BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260219T190000
DTEND;TZID=Africa/Nairobi:20260219T203000
DTSTAMP:20260527T002115
CREATED:20260218T181534Z
LAST-MODIFIED:20260407T102753Z
UID:40973-1771527600-1771533000@kesho-kenya.org
SUMMARY:Management of Biliary and Gall Bladder Tumours
DESCRIPTION:SUMMARY \nAdvances in the Multidisciplinary Management of Biliary and Gallbladder Tumours \nSpeakers: Prof. Elly Ogutu\, Dr. Mohan Ramchandani\, Dr. Kausik Bhattacharya\, Dr. M. Vamshi Krishna \nDate: 19 February 2026 \nThis session examined the management of biliary and gallbladder tumours through a multidisciplinary lens\, highlighting the importance of coordinated approaches across endoscopy\, surgery and oncology in improving patient outcomes. \nA central theme was the role of accurate and timely diagnosis\, with particular emphasis on tissue acquisition and the contribution of advanced endoscopic techniques in guiding clinical decision-making. The discussion underscored how delays or limitations in diagnostic pathways can significantly influence treatment options and outcomes. \nThrough the KNH–UoN strategic training partnership and collaboration with the Asian Institute of Gastroenterology\, the session reflected the value of regional expertise and diaspora engagement in strengthening clinical capacity and expanding access to specialised skills. \nFrom a clinical perspective\, evolving therapeutic strategies—including advances in surgical techniques and radiation oncology—were highlighted as critical components of care\, particularly when integrated within a multidisciplinary framework that supports individualized treatment planning. \nAcross the session\, a consistent message emerged: improving outcomes in biliary and gallbladder cancers will depend on strengthening diagnostic pathways and ensuring coordinated\, multidisciplinary care across the patient journey. \nKey Takeaways \n\nEarly and accurate diagnosis remains central to effective management.\nAdvanced endoscopic techniques play a key role in tissue sampling and staging.\nMultidisciplinary coordination improves treatment planning and outcomes.\nRegional and diaspora collaboration strengthens clinical capacity.\nIntegration of surgical\, endoscopic and oncological care is essential.
URL:https://kesho-kenya.org/event/management-of-biliary-and-gall-bladder-tumours/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/02/WhatsApp-Image-2026-02-18-at-10.47.07-AM-e1771438592764.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260226T190000
DTEND;TZID=Africa/Nairobi:20260226T203000
DTSTAMP:20260527T002115
CREATED:20260223T194335Z
LAST-MODIFIED:20260319T173215Z
UID:41036-1772132400-1772137800@kesho-kenya.org
SUMMARY:Precision Pathways in Lymphoma
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nDate: 26th February 2026Time: 7:00 PM – 8:30 PM (EAT) \n\nSpeakers \nModeratorDr Anne MwirigiConsultant Haematologist & Assistant Professor\, AKUH \nDr Rohini RadiaConsultant in BMT and Haematology\, Nairobi West HospitalStrategic Alignment in Lymphoma: From Precise Diagnosis to Clinical Excellence \nDr Jonathan WawireConsultant Anatomic Pathologist & Assistant Professor\, AKUHLymphoma Diagnostic Algorithm in Routine Practice \nHighlights\nThis session explored how lymphoma care is increasingly shaped by the alignment between diagnostic precision and therapeutic decision-making\, particularly in settings where access to advanced diagnostics remains variable. \nA central theme was the shift from morphology-led classification alone to a multi-parameter diagnostic approach\, integrating clinical context\, histopathology\, immunophenotyping and where available\, molecular profiling. As emphasized during the discussion\, classification is no longer purely descriptive: it directly determines treatment pathways\, prognosis and eligibility for emerging therapies. \nDr. Wawire outlined a structured diagnostic framework anchored on architecture\, cytology and clonality\, with morphology guiding the initial pathway and targeted immunohistochemistry refining classification. In routine practice\, a focused IHC panel (CD20\, CD3\, CD5\, CD10\, Cyclin D1) remains sufficient to classify most lymphomas and support timely clinical decisions. \nImportantly\, the session addressed the practical realities of diagnostic limitations. The distinction between “Not Otherwise Specified (NOS)” and “Not Further Classified (NFC)” was highlighted as a clinically responsible approach where molecular testing is unavailable maintaining transparency while ensuring patients are still appropriately managed. \nBuilding on this\, Dr. Radia emphasized that improved outcomes depend on early alignment between diagnostics\, treatment selection and delivery systems. In practice\, delays in diagnostic workflows or limited access to molecular testing can directly influence treatment choices and patient outcomes making coordination across pathology\, oncology and imaging essential. \nAs treatment options expand\, from immunochemotherapy to targeted agents\, CAR-T therapies and bispecific antibodies\, the need for early risk stratification and timely decision-making becomes even more critical\, particularly in balancing efficacy\, cost and access within real-world settings. \nAcross the case discussions\, a consistent message emerged: the quality and timeliness of diagnosis remain central to achieving better outcomes in lymphoma care. \nKey takeaways: \n\nLymphoma classification now relies on integrated clinical\, morphological and molecular assessment.\nFocused IHC panels remain highly effective in routine and resource-limited settings.\n“NFC” supports safe\, transparent reporting when advanced testing is unavailable.\nDiagnostic delays and access gaps can directly impact treatment decisions.\nEarly alignment across disciplines is essential to optimize outcomes.
URL:https://kesho-kenya.org/event/precision-pathways-in-lymphoma/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/02/WhatsApp-Image-2026-02-23-at-10.02.59-PM-e1771875762948.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260305T190000
DTEND;TZID=Africa/Nairobi:20260305T203000
DTSTAMP:20260527T002115
CREATED:20260303T081324Z
LAST-MODIFIED:20260303T083141Z
UID:41277-1772737200-1772742600@kesho-kenya.org
SUMMARY:Women in Oncology
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nWomen in Oncology this International Women’s Day! \nJoin us for a powerful CPD Accredited webinar hosted by KESHO — Kenya Society of Haematology & Oncology \nDate: 5th March 2026 \nTime: 7:00 PM – 8:30 PM EAT \nModerator: \n\nDr. Gladwell Kiarie — Medical Oncologist\, The Nairobi Hospital\n\nSpeakers: \n\nProf. Verna Vanderpuye\n\nSenior Consultant Clinical Oncologist & Deputy Director\, National Centre of Radiotherapy\, Oncology and Nuclear Medicine\, Korle-bu Teaching Hospital\, Accra\, Ghana Topic: Legacy and Leadership: Mentorship from Women Advancing Oncology in Africa \n\nDr. Chemtai Mungo\n\nAssistant Professor of Obstetrics and Gynaecology & Physician-Scientist\, University of North Carolina at Chapel Hill Topic: Purpose-Driven Careers: Global Health\, Research and Women’s Impact in Oncology \n\nDr. Anne Mwirigi\n\nConsultant Haematologist and Assistant Professor\, Aga Khan University Hospital Topic: Growing in Specialised Oncology: Lessons in Haematology \n\nProf. Nazik Hammad\n\nProfessor of Medical Oncology\, Saint Michael’s Hospital and University of Toronto Topic: Building Impactful Careers in Global Oncology: Mentorship\, Leadership and Equity in Cancer Care[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_btn title=”CLICK TO REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_2lIM-Q1-Rm6JSxlo9b0jmQ”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/women-in-oncology-2/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-03-at-8.06.46-AM-e1772525890478.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260312T190000
DTEND;TZID=Africa/Nairobi:20260312T203000
DTSTAMP:20260527T002115
CREATED:20260310T140249Z
LAST-MODIFIED:20260319T174323Z
UID:41385-1773342000-1773347400@kesho-kenya.org
SUMMARY:Multiple Myeloma Care in Western Kenya
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]Event Title: The Journey of Multiple Myeloma Care in Western Kenya \nAccreditation: CPD Accredited \n\nDate: 12th March 2026\nTime: 7 PM – 8:30 PM EAT\nOrganization: KESHO (Kenya Society of Haematology & Oncology)\n\nModerator:  \n\nDr. Matilda Ongondi: Consultant Physician and Clinical Haemato-Oncologist\, Kenyatta National Hospital.\n\nSpeakers \n\n\n\n\nDr. Teresa Lotodo: Senior Lecturer & Consultant Pathologist (AP/CP)Topic: Modern Diagnostic Paradigms in Multiple Myeloma: From Morphology to Molecular Risk Stratification \nDr. Rohini Radia: Consultant in BMT and HaematologyTopic: Contemporary Management of Multiple Myeloma: Sequencing\, Cellular Therapies and Risk-Adapted Strategies \nDr. Beatrice Melly: Clinical Haematologist\, Moi Teaching and Referral HospitalTopic: Building Sustainable Myeloma Care Pathways: Access\, Infrastructure and Multidisciplinary Integration \nHightlights\n\n\n\n\n\n\n\n\nThis session examined how multiple myeloma care is evolving within the Kenyan context\, bringing together perspectives on diagnostics\, treatment advances and system-level delivery. \nA central theme was the contrast between rapid global therapeutic progress and the realities of access and infrastructure in low- and middle-income settings. While survival outcomes have improved significantly with the introduction of proteasome inhibitors\, immunomodulatory agents and anti-CD38 therapies\, translating these gains into routine practice remains uneven. \nThe discussion highlighted the importance of accurate and timely diagnosis\, with a shift from morphology-based approaches towards molecular and cytogenetic risk stratification to guide treatment decisions. \nFrom a clinical perspective\, modern management is increasingly risk-adapted\, incorporating quadruplet induction regimens\, autologous stem cell transplantation and maintenance strategies. Emerging therapies\, including CAR-T cells and bispecific antibodies are redefining outcomes in relapsed disease\, though access remains limited in many settings. \nAt a systems level\, the AMPATH multiple myeloma program was presented as a model of how coordinated care can be built through partnerships\, integrating clinical care\, training and research within a learning health system. The approach emphasizes improving access\, strengthening diagnostic and treatment infrastructure\, and embedding multidisciplinary care pathways to support patients across the disease course. \nAcross the session\, a consistent message emerged: advancing myeloma care requires not only better therapies\, but systems capable of delivering them. \nKey Takeaways \n\nMyeloma outcomes are improving with novel and combination therapies.\nAccurate diagnosis and risk stratification are central to management.\nStandard care includes quadruplet induction\, ASCT and maintenance therapy.\nCAR-T and bispecific antibodies are reshaping relapsed disease care.\nSustainable progress depends on access\, infrastructure and integrated care models.
URL:https://kesho-kenya.org/event/multiple-myeloma-care-in-western-kenya/
CATEGORIES:CME 2026,Conferences,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-10-at-11.40.58-AM-1-e1773151318490.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260319T190000
DTEND;TZID=Africa/Nairobi:20260319T203000
DTSTAMP:20260527T002115
CREATED:20260318T112347Z
LAST-MODIFIED:20260319T174535Z
UID:41463-1773946800-1773952200@kesho-kenya.org
SUMMARY:Renal Cell Carcinoma: Evidence-Based Integration of Surgery and Systemic Therapy
DESCRIPTION:Evidence-Based Integration of Surgery and Systemic Therapy \nDate: 19th March 2026Time: 7 PM – 8:30 PM EAT \nMODERATORDr. Amina K. HabibMedical Oncologist\, Aga Khan University Hospital\, Nairobi \nDr. Carnjini YogeswaranConsultant Urological Surgeon | Kenyatta National HospitalTopic: Surgical Management of Locally Advanced and Oligometastatic Renal Cell Carcinoma \nDr. Douglas NyandikaPhysician and Medical Oncologist | The Nairobi HospitalTopic: Adjuvant and Metastatic Systemic Therapy in Renal Cell Carcinoma \nHighlights\nThis session examined the evolving management of renal cell carcinoma (RCC)\, focusing on how surgical and systemic approaches are increasingly integrated across the disease continuum. \nA central theme was the importance of risk-adapted\, multidisciplinary care\, particularly in settings where many patients are still present with advanced diseases. While improved imaging has increased incidental detection globally\, late-stage presentation remains common in Kenya\, shaping both prognosis and treatment strategy. \nFrom a surgical perspective\, nephron-sparing surgery remains standard for localized diseases\, while radical nephrectomy and complex resections play a critical role in locally advanced cases. In oligometastatic disease\, cytoreductive nephrectomy and metastasis-directed therapy may offer benefit in carefully selected patients\, particularly when integrated with systemic treatment strategies. \nSystemic therapy has expanded significantly\, with immune checkpoint inhibitors and targeted therapies now forming the backbone of treatment in advanced disease. Evidence from key trials demonstrates improved survival outcomes with combination regimens\, reinforcing a shift towards early and strategic use of systemic therapy\, particularly in metastatic and high-risk settings. \nIn the adjuvant setting\, therapies such as pembrolizumab have shown disease-free and overall survival benefit in selected high-risk patients\, highlighting the importance of post-surgical risk stratification and follow-up. \nHowever\, translating these advances into routine practice remains constrained by access\, cost and infrastructure. The discussion underscored the need for context-specific treatment pathways\, supported by multidisciplinary decision-making and strengthened health systems. \nAcross the session\, a consistent message emerged: optimal RCC outcomes depend on deliberate integration—of surgery\, systemic therapy and patient-centered decision-making. \nKey Takeaways \n\nRCC management requires integration of surgical and systemic therapies.\nLate-stage presentation remains a key challenge in many settings.\nNephron-sparing and radical surgery remain central to localized and advanced disease.\nImmunotherapy and targeted agents are transforming metastatic RCC outcomes.\nAdjuvant therapy is increasingly relevant in high-risk post-surgical patients.\nAccess\, cost and infrastructure continue to shape real-world implementation.\n\n 
URL:https://kesho-kenya.org/event/renal-cell-carcinoma-2/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-18-at-10.33.25-AM-e1773833004541.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260326T190000
DTEND;TZID=Africa/Nairobi:20260326T203000
DTSTAMP:20260527T002115
CREATED:20260324T112204Z
LAST-MODIFIED:20260324T112936Z
UID:41493-1774551600-1774557000@kesho-kenya.org
SUMMARY:Optimizing Care in Colorectal Cancer
DESCRIPTION:Date: 26th March 2026 \nTime: 7 PM – 8:30 PM EAT \nModerator \n\nDr. Andrew Odhiambo Medical Oncologist\, The Nairobi Hospital; Thematic Head & Program Director\, Medical Oncology\, UON\n\nSpeakers \nDr. Alex Muturi Colorectal Surgeon & Surgical Gastroenterologist\, Kenyatta University Teaching\, Research and Referral Hospital Locally Advanced Colon Cancer: Timing of Surgery Relative to Systemic Treatment \nDr. Caroline Tonio Medical Oncologist\, Clinical Research Fellow (Clinical Trials)\, The Christie NHS Foundation Trust\, UK & KUTRRH\, Kenya “Too Young for Colorectal Cancer?” Understanding the rise of EOCRC and its clinical impact. \n    	\n        CLICK TO REGISTER
URL:https://kesho-kenya.org/event/optimizing-care-in-colorectal-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-24-at-8.25.12-AM-e1774351309301.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260409T190000
DTEND;TZID=Africa/Nairobi:20260409T203000
DTSTAMP:20260527T002115
CREATED:20260407T093519Z
LAST-MODIFIED:20260525T192253Z
UID:41540-1775761200-1775766600@kesho-kenya.org
SUMMARY:Treatment in Esophageal Cancer
DESCRIPTION:THE ROLE OF MULTIMODAL Treatment in Esophageal Cancer \nDate: 9th April 2026 Time: 7 PM – 8:30 PM EAT \nMODERATOR \nDr. Omar Abdihamid Clinical Oncologist\, Garissa Regional Cancer Center | Vice President (EA)\, African Organisation for Research and Training in Cancer \nSPEAKERS \nDr. Juma Odoro Cardiothoracic and vascular surgeon\, JOOTRH Kisumu and Head of Unit Surgical Management of Esophageal Cancer \nDr. Rogers Mongare Consultant Clinical and Radiation Oncologist at Kenyatta National Hospital (KNH) The Role of Radiotherapy in the Management of Esophageal Cancer \nDr. Kevin Makori Consultant Clinical & Radiation Oncologist\, Homa Bay County Teaching and Referral Hospital | Clinical Trials Investigator\, Victoria Cancer Care & Research Center\, Nyamira Management of Metastatic Esophageal Cancer: Advances in Targeted and Combination Therapies \n    	\n        CLICK TO REGISTER
URL:https://kesho-kenya.org/event/treatment-in-esophageal-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/04/WhatsApp-Image-2026-04-07-at-12.13.58-PM-e1775554431579.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260409T190000
DTEND;TZID=Africa/Nairobi:20260509T203000
DTSTAMP:20260527T002115
CREATED:20260526T192731Z
LAST-MODIFIED:20260526T193025Z
UID:41708-1775761200-1778358600@kesho-kenya.org
SUMMARY:The Role of Multimodal Treatment in Esophageal Cancer
DESCRIPTION:Moderator: Dr. Omar Abdihamid\nSpeakers: Dr. Juma Odoro\, Dr. Rogers Mongare\, Dr. Kevin Makori\nDate: 9 April 2026\n\nThis session examined esophageal cancer management through a multidisciplinary lens\, bringing together surgical\, radiotherapeutic and systemic treatment perspectives across the continuum of care. \nA central theme was that treatment selection depends on accurate staging\, patient fitness\, disease burden and early alignment between disciplines. In many African settings\, patients may present with locally advanced disease and nutritional compromise\, making timely diagnosis\, staging and supportive care central to outcomes. \nThe surgical discussion focused on the role of resection in appropriately selected patients\, where careful assessment of resectability\, operative risk\, nodal disease and perioperative optimisation shape whether surgery can offer curative benefit. The session also reinforced that surgery is rarely a standalone decision; it must be integrated with oncology input and long-term follow-up. \nRadiotherapy was addressed as part of multimodal care\, with roles in neoadjuvant\, definitive\, adjuvant and palliative pathways depending on stage and patient factors. The discussion highlighted the need for precise planning\, symptom control and realistic treatment pathways that reflect available infrastructure and patient access. \nIn metastatic disease\, systemic therapy remains central\, with evolving use of combination approaches\, targeted treatment and biomarker-directed strategies. However\, implementation must be balanced with access\, cost\, toxicity\, performance status and local service realities. \nAcross the session\, a consistent message emerged: esophageal cancer care requires deliberate sequencing—matching the right treatment to the right patient at the right point in the disease course. \nKey Takeaways\n\nEsophageal cancer management depends on accurate staging\, nutrition assessment and multidisciplinary planning.\nSurgery remains important in resectable disease but requires careful patient selection and perioperative optimisation.\nRadiotherapy has curative\, consolidative and palliative roles within multimodal treatment.\nMetastatic disease management is evolving with systemic combinations and biomarker-driven options.\nAccess\, treatment tolerance and supportive care shape real-world implementation in Kenya and the wider region.\nEarly referral and MDT decision-making are critical to improving outcomes.
URL:https://kesho-kenya.org/event/the-role-of-multimodal-treatment-in-esophageal-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2026/05/The-Role-of-Multimodal-Treatment-in-Esophageal-Cancer-e1779823765248.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260416T190000
DTEND;TZID=Africa/Nairobi:20260416T203000
DTSTAMP:20260527T002115
CREATED:20260526T192507Z
LAST-MODIFIED:20260526T193940Z
UID:41705-1776366000-1776371400@kesho-kenya.org
SUMMARY:Bridging Surgery and Oncology in Head & Neck Cancer
DESCRIPTION:Moderator: Dr. Ahmed Komen\nSpeakers: Dr. Anthony Kenyanya\, Dr. Anthony Ndiritu\nDate: 16 April 2026\n\nThis session explored the management of head and neck cancer with particular attention to how surgical decisions and oncology pathways must align from the outset. Through oral cavity cancer as a key focus\, the session examined resectability\, margins\, nodal management\, reconstruction\, adjuvant therapy and functional outcomes. \nA central theme was that treatment planning must go beyond tumour removal. Dr. Anthony Kenyanya highlighted the importance of staging\, imaging\, pathology\, dental and nutritional assessment\, surgical access\, margin planning and neck node evaluation. In oral cavity cancers\, surgical success depends not only on clear oncologic resection\, but also on the ability to reconstruct defects and preserve speech\, swallowing\, appearance and quality of life. \nThe discussion also emphasised the challenge of late presentation and complex anatomy. Selective neck dissection\, sentinel node considerations\, access procedures such as mandibulotomy\, and the reconstructive ladder were framed as tools for balancing disease control with morbidity. The role of the pathologist and margin assessment was highlighted as central to determining risk and guiding further treatment. \nDr. Anthony Ndiritu built on this by outlining how radiotherapy and chemoradiation fit into early\, locally advanced\, post-operative\, recurrent and metastatic diseases. Early-stage disease may often be treated with a single modality\, while locally advanced disease requires careful integration of surgery\, radiotherapy and chemotherapy. \nPositive margins and extranodal extension were discussed as major indications for post-operative chemoradiation\, with timely initiation of treatment after surgery being important. The session also addressed treatment technique\, patient fitness\, nutrition\, supportive care and the need to tailor recommendations to the services and expertise available. \nAcross the session\, a consistent message emerged: head and neck cancer care is as much about function\, coordination and follow-through as it is about disease control. \nKey Takeaways\n\nHead and neck cancer decisions must integrate tumour stage\, resectability\, patient fitness and functional outcomes.\nMargin planning\, pathology reporting and neck node assessment directly shape adjuvant treatment decisions.\nSurgery requires strong reconstruction and rehabilitation planning to preserve speech\, swallowing and appearance.\nLocally advanced disease often needs combined-modality treatment through an MDT approach.\nPositive margins and extranodal extension are key triggers for post-operative chemoradiation.\nSupportive care\, nutrition and patient navigation are essential to treatment completion.
URL:https://kesho-kenya.org/event/bridging-surgery-and-oncology-in-head-neck-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2026/05/Bridging-Surgery-and-Oncology-in-Head-Neck-Cancer-e1779824360609.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260430T190000
DTEND;TZID=Africa/Nairobi:20260430T203000
DTSTAMP:20260527T002115
CREATED:20260526T192028Z
LAST-MODIFIED:20260526T194041Z
UID:41701-1777575600-1777581000@kesho-kenya.org
SUMMARY:Multidisciplinary Management of Testicular Cancer
DESCRIPTION:Moderator: Dr. Muigai Mararo\nSpeakers: Dr. Dedan Opondo\, Dr. Joseph Abuodha\, Dr. George Ogweno\nDate: 30 April 2026\n\nThis session marked Testicular Cancer Awareness Month with a multidisciplinary discussion on diagnosis\, primary management\, advanced disease\, relapse and fertility preservation. \nA central theme was that testicular cancer is highly curable when investigated and managed promptly\, but cure depends on disciplined staging and risk stratification. Dr. Dedan Opondo outlined the importance of early clinical recognition\, scrotal ultrasound\, serum tumour markers\, cross-sectional imaging and radical inguinal orchiectomy. The session reinforced that suspected testicular cancer should not be delayed\, particularly because some germ cell tumours can progress rapidly. \nStaging was presented as a practical foundation for management. Tumour markers such as AFP\, beta-HCG and LDH\, together with nodal imaging and histology\, help distinguish seminomatous from non-seminomatous disease and guide decisions on surveillance\, chemotherapy\, radiotherapy and retroperitoneal lymph node dissection. The discussion also highlighted the technical and fertility-related implications of retroperitoneal surgery in young men. \nDr. Joseph Abuodha reviewed advanced and relapsed disease\, emphasising that treatment remains strongly anchored in surgery\, cisplatin-based chemotherapy\, radiotherapy and surveillance rather than newer targeted or immunotherapy approaches. Across stages\, the emphasis was on matching intensity to risk—avoiding both overtreatment and undertreatment—while recognising that even metastatic disease can remain curable with the right treatment strategy. \nDr. George Ogweno brought fertility preservation into the core of cancer care. He underscored the need for early oncofertility counselling\, sperm banking where possible before treatment\, and stronger collaboration between oncology\, urology\, fertility specialists\, laboratories and counsellors. The discussion also reflected Kenya’s service realities\, including limited fertility centres and the need for clearer pathways\, consent and long-term storage planning. \nAcross the session\, a consistent message emerged: testicular cancer care must protect both survival and survivorship. \nKey Takeaways\n\nEarly recognition\, tumour markers\, imaging and radical inguinal orchiectomy are central to initial management.\nRisk stratification using histology\, TNM stage and post-operative markers guides treatment intensity.\nSeminoma and non-seminoma pathways differ and should not be managed interchangeably.\nCisplatin-based chemotherapy remains central in advanced and relapsed disease.\nSurveillance is appropriate only when reliable follow-up is possible.\nFertility counselling and sperm preservation should be discussed as early as possible.
URL:https://kesho-kenya.org/event/multidisciplinary-management-of-testicular-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2026/05/Multidisciplinary-Management-of-Testicular-Cancer.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260507T190000
DTEND;TZID=Africa/Nairobi:20260507T203000
DTSTAMP:20260527T002115
CREATED:20260525T193909Z
LAST-MODIFIED:20260525T210319Z
UID:41667-1778180400-1778185800@kesho-kenya.org
SUMMARY:From Data to Discovery: Leveraging Registries and Clinical Insights to Advance Research
DESCRIPTION:Moderator: Rebecca Mwakichako\nDate: 7th May 2026\nSpeakers: Dr. Thomas Chatzikonstantinou\, Ms. Anne Korir \nThis session examined how routine clinical data can be transformed into meaningful research evidence\, with a focus on real-world data\, clinical registries and everyday documentation as a foundation for local oncology research. \nA central theme was the value of real-world evidence as a complement to randomized controlled trials. Dr. Thomas Chatzikonstantinou outlined how registries and clinical databases can help answer questions on treatment patterns\, long-term outcomes\, low-prevalence biomarkers\, health economics and implementation across diverse settings. He emphasized that good research begins with realistic questions\, clear endpoints and attention to data quality. \nMs. Anne Korir grounded the discussion in the Kenyan cancer registry experience\, highlighting how paper files\, unstructured notes\, missing staging information\, weak follow-up documentation and inconsistent residence or risk-factor data can limit the research value of clinical records. She underscored the need for standardization\, digitization\, regular data cleaning and ethical governance. \nAcross the session\, a consistent message emerged: every clinical encounter can contribute to discovery when documentation is structured\, complete and designed with future learning in mind. \n  Key Takeaways \n\nReal-world data complements clinical trials by showing how care is delivered in routine practice.\nRoutine clinical notes can generate locally relevant oncology research questions.\nStandardized documentation is essential for usable research and registry data.\nCancer registries remain critical for surveillance\, policy and outcome tracking.\nCollaboration between clinicians\, registries and research institutions can strengthen local evidence generation.\n\n  \n 
URL:https://kesho-kenya.org/event/from-data-to-discovery-leveraging-registries-and-clinical-insights-to-advance-research/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/From-Data-to-Discovery.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260514T190000
DTEND;TZID=Africa/Nairobi:20260514T203000
DTSTAMP:20260527T002115
CREATED:20260525T203403Z
LAST-MODIFIED:20260525T210044Z
UID:41670-1778785200-1778790600@kesho-kenya.org
SUMMARY:Melanoma Care in Practice: Integrating Dermatology\, Surgery & Oncology
DESCRIPTION:Moderator: Dr Stephen Chege\nDate: 14th May 2026\nSPEAKERS: Dr. Hannah Wanyika\, Dr. Esther Gathura\, Dr. Angela McLigeyo \nThis session examined melanoma care across the clinical pathway\, from recognition of suspicious skin lesions to biopsy\, excision\, reconstruction\, staging and systemic treatment. \nA central theme was the importance of early suspicion and timely tissue diagnosis. Dr. Hannah Wanyika highlighted practical indications for biopsy\, including new or changing pigmented lesions\, non-healing ulcers\, evolving moles and lesions that differ from surrounding skin. The discussion reinforced the use of the ABCDE approach and the “ugly duckling” sign\, while emphasizing that changing lesions on the palms\, soles\, nails and scalp should not be dismissed. \nDr. Esther Gathura explored the surgical and reconstructive dimensions of melanoma care\, particularly the realities of acral melanoma\, which is common in African populations and often presents late. She emphasized the role of mapping biopsies\, Breslow thickness\, ulceration\, nodal assessment and multidisciplinary planning in balancing oncologic safety with function\, especially for weight-bearing areas of the foot. \nDr. Angela McLigeyo outlined the major advances in systemic therapy for advanced melanoma\, including immune checkpoint inhibitors\, targeted therapy and emerging treatment strategies. While immunotherapy has transformed outcomes globally\, the session also acknowledged access\, affordability and the urgent need for local data to guide treatment decisions in Kenya and the region. \nAcross the session\, a consistent message emerged: optimal melanoma care depends on early recognition\, accurate biopsy\, careful staging\, function-preserving surgery and realistic access to effective systemic therapy. \nKey Takeaways \n\nChanging pigmented lesions\, non-healing ulcers and suspicious nail or acral lesions require timely biopsy.\nThe ABCDE rule and “ugly duckling” sign remain useful tools in clinical assessment.\nAcral melanoma presents distinct diagnostic and surgical challenges in African settings.\nSurgical management must balance clear margins\, staging and functional reconstruction.\nImmunotherapy and targeted treatment have changed advanced melanoma care\, but access and local evidence remain key challenges.
URL:https://kesho-kenya.org/event/melanoma-care-in-practice-integrating-dermatology-surgery-oncology/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/Melanoma-Care.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260521T190000
DTEND;TZID=Africa/Nairobi:20260521T203000
DTSTAMP:20260527T002115
CREATED:20260525T210458Z
LAST-MODIFIED:20260526T194356Z
UID:41677-1779390000-1779395400@kesho-kenya.org
SUMMARY:Bladder Cancer Care
DESCRIPTION:SPEAKERS: Dr. Patrick Mbuthia\, Dr. Helena Musau\, Dr Mohammed Ezzi\nDate: 21st May 2026\nModerator: Dr. Sitna Mwanzi \nThis session examined bladder cancer through a multidisciplinary lens\, bringing together surgical\, radiotherapeutic and systemic treatment perspectives across the continuum of care. \nA central theme was the need for accurate staging and risk-adapted management. Dr. Patrick Mbuthia discussed the role of transurethral resection of bladder tumour (TURBT) in diagnosis\, staging and treatment\, particularly for non-muscle invasive disease. The importance of complete resection\, adequate detrusor muscle in the specimen\, careful imaging and attention to complications was emphasized as central to subsequent treatment decisions. \nDr. Helena Musau highlighted the evolving role of radiotherapy in bladder preservation\, especially through tri-modality therapy combining maximal TURBT\, concurrent chemoradiation and structured response assessment. The discussion also addressed patient selection\, surveillance\, salvage options\, palliative radiotherapy for symptoms\, and the value of newer radiotherapy techniques in reducing toxicity while preserving quality of life. \nDr. Mohammed Ezzi reviewed systemic treatment across non-muscle invasive\, muscle invasive and metastatic bladder cancer. He outlined the role of intravesical therapy\, BCG\, cisplatin eligibility\, immunotherapy\, maintenance strategies and emerging options such as antibody-drug conjugates and targeted agents\, while noting that cost and availability continue to shape real-world treatment in Kenya. \nAcross the session\, a consistent message emerged: improving bladder cancer outcomes requires timely diagnosis\, high-quality TURBT\, multidisciplinary decision-making and treatment pathways that reflect both evidence and local access reality. \nKey Takeaways \n\nBladder cancer management depends on accurate staging and distinction between non-muscle invasive and muscle invasive disease.\nHigh-quality TURBT with adequate muscle sampling is central to diagnosis and treatment planning.\nTrimodality therapy offers bladder preservation for carefully selected patients.\nSystemic therapy is rapidly evolving with immunotherapy\, maintenance approaches and antibody-drug conjugates.\nLocal data are needed to address African patterns of disease\, including schistosomiasis-associated squamous cell carcinoma.\n\n 
URL:https://kesho-kenya.org/event/bladder-cancer-care/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/Bladder-Cancer-Care-e1779824625799.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260528T190000
DTEND;TZID=Africa/Nairobi:20260528T203000
DTSTAMP:20260527T002115
CREATED:20260525T190142Z
LAST-MODIFIED:20260526T114254Z
UID:41658-1779994800-1780000200@kesho-kenya.org
SUMMARY:Advancing Care Through Multidisciplinary Collaboration
DESCRIPTION:The Brain Tumour JourneyAdvancing Care Through Multidisciplinary Collaboration \nDate: 28th May 2026Time: 7 PM – 8:30 PM EATwww.kesho-kenya.org \nSpeakers & Topics\nDr. Michael MagohaConsultant Neurological Surgeon & Lecturer\, University of Nairobi\, Co-Founder Brain Tumor Association of KenyaThe Beginning of the Brain Tumor Journey – A Neurosurgeon’s Perspective \nDr. Sarah MumaPaediatric Haemato-Oncologist\, Kenyatta National HospitalMultidisciplinary Management of Brain Tumors: Optimizing Outcomes Through Collaborative Care \nParmenas Minda OkwemaSenior Lecturer\, Department of Human Pathology\, University of Nairobi\, Chairman and Founder\, Brain Tumor Association of KenyaUnderstanding Brain Tumour Diagnosis: Pathology Principles and Diagnostic Challenges \nRN Celine KilanyaPaediatric Oncology Nurse\, Kenyatta National HospitalHolistic and Supportive Care in Brain Tumour Management: The Oncology Nurse’s Role in Patient Navigation \nMr. David L. Oluoch-Olunya (Moderator)Consultant Neurological Surgeon\, The Nairobi Hospital & Senior Lecturer\, Aga Khan University Hospital \n    	\n        CLICK TO REGISTER
URL:https://kesho-kenya.org/event/advancing-care-through-multidisciplinary-collaboration/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/WhatsApp-Image-2026-05-26-at-8.18.55-AM.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20261119T080000
DTEND;TZID=Africa/Nairobi:20261121T170000
DTSTAMP:20260527T002115
CREATED:20260407T183641Z
LAST-MODIFIED:20260519T095620Z
UID:41566-1795075200-1795280400@kesho-kenya.org
SUMMARY:The 9th Kenya International Cancer Conference
DESCRIPTION:
URL:https://kesho-kenya.org/event/2026-kenya-international-cancer-conference/
CATEGORIES:Conferences,Webinar Recording Available
END:VEVENT
END:VCALENDAR